News Release

以浆细胞样树突状细胞为治疗标靶可减轻皮肤型狼疮症状

Peer-Reviewed Publication

American Association for the Advancement of Science (AAAS)

Targeting Plasmacytoid Dendritic Cells Can Reduce Cutaneous Lupus Symptoms (1 of 1)

video: Jodi Karnell, Sr. director, research, Horizon Therapeutics, discusses how HZN-7734 depletes plasmacytoid dendritic cells and demonstrates clinical benefit in cutaneous lupus. This material relates to a paper that appeared in the May 26, 2021, issue of <i>Science Translational Medicine</i>, published by AAAS. The paper, by J.L. Karnell at Viela Bio in Gaithersburg, MD; and colleagues was titled, "Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus." view more 

Credit: Horizon Therapeutics

Jodi Karnell和同事研发了一种名为VIB7734的单克隆抗体,它可通过设靶和耗竭血液和皮肤中的浆细胞样树突状细胞(pDC)来降低皮肤狼疮患者症状的严重程度。研究人员发现,在两项涉及总共67名自身免疫性疾病(如狼疮)患者的I期临床试验中,用VIB7734进行治疗与安慰剂一样安全,但它却能显着降低pDC的出现频率。该抗体还可降低皮肤中的一组被称为1型干扰素的关键性免疫蛋白的活性。pDCs和1型干扰素涉嫌在包括狼疮在内的自身免疫疾病中起着某种作用;因此,如果这些初期结果得到进一步临床试验的支持,该新型抗体或是有效对抗自身免疫的治疗选择。VIB7734会以一种pDCs的表面分子为标靶并减少这些细胞;在仅给予单剂量的VIB7734后,非人类灵长动物和自身免疫性疾病患者体内的pDCs数目常会减半。在接受大剂量(150毫克)VIB7734治疗的皮肤性狼疮患者中,有87.5%的患者会在治疗1个月后症状得到具临床意义的减轻;相比之下,接受50毫克治疗的患者中有37.5%的人症状有所减轻,而安慰剂组的人中该比例为28.6%。Karnell等人还注意到,VIB7734似乎对循环血中具高浓度1型干扰素患者的效果最好,提示I型干扰素的基线浓度可预测患者的治疗反应。

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.